Arvinas ARVN Return on equity

Return on equity at other companies

Nurix Therapeutics, Inc.NRIX

-80.3%+113pp

LON

LeonaBio, Inc.LONA

-298.8%-726pp

Kymera TherapeuticsKYMR

-24.2%-5.2pp

Monte Rosa Therapeutics, Inc.GLUE

-42.7%—

Relmada Therapeutics, Inc.RLMD

-48.8%-20.0pp

ArriVent BioPharma, Inc.AVBP

-55.2%+8.0pp

FAQ

What is Arvinas's return on equity?

Arvinas (ARVN) reported return on equity of -42.3% in Q1 2026.

How has Arvinas's return on equity changed year-over-year?

Arvinas's return on equity decreased by 476.0% year-over-year, from -7.3% to -42.3%.

What is the long-term trend for Arvinas's return on equity?

Over 5 years (2020 to 2025), Arvinas's return on equity has grown at a -10.0% compound annual growth rate (CAGR), from -27.5% to -16.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.